지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Background: Chemotherapy-induced peripheral neuropathy (CIPN) involving sensory and motor nerve damage or dysfunction is a common and serious clinical problem that affects many patients receiving cancer treatment. This condition may pose challenges for the clinician to diagnose and manage, particularly in patients with coexisting conditions or disorders that involve the peripheral nervous system. Many chemotherapeutic agents used today are associated with the development of serious and dose-limiting CIPN that can adversely affect the administration of planned therapy and can impair quality of life by interference with the patients’ activities of daily living. The most important clinical objective in the evaluation of patients with CIPN is to determine their level of functional impairment involving activities of daily living.
These findings are used to make medical decisions to continue, modify, delay, or stop treatment. The most commonly reported drugs to cause CIPN include taxanes, platinum agents, vinca alkaloids, thalidomide, and bortezomib. We aimed to determine PN incidence during cisplatin, carboplatin and oxaliplatin administration. Methods: We collected data from 125 patients who received at least one cycle of cisplatin, carboplatin or oxaliplatin. They completed a self-reported questionnaire and items related to their disease and peripheral neuropathy. The investigators filled in part of items about disease and treatment. Patient Neurotoxicity Qeustionnaire developed by Bionumerik company were applied for PN assessment. Results: The incidences of sensory neurotoxicities of cisplatin, carboplatin and oxaliplatin were respectively 23%, 56% and 50%. The incidences of motor neurotoxicities of cisplatin, carboplatin and oxaliplatin were respectively 18%, 42% and 19%. The incidences of severe neurotoxicities of cisplatin, carboplatin and oxaliplatin were respectively 13%, 28% and 14%. The incidences of PN were associated with cumulative dose but not age, gender and concurrent illness.
19.2% of the patients (24/125) were prescribed with gabapentin, nortriptyline or gabapentin plus nortriptyline to reduce these peripheral symptoms and 75% of the patients answered the drug were effective. Conclusion: Incidence of PN after cisplatin or oxaliplatin administration is cumulative dose-related. Physician-based assessments under-reported the incidence and severity of CIPN. To overcome this limitation, diagnostic tools specifically designed to assess peripheral neuropathy severity associated with chemotherapy must be developed.
목차
등록된 정보가 없습니다.
참고문헌 (16)
참고문헌 신청
Andreas A.Argyriou / 2005 / Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid
Constance Visovsky / 2007 / Putting Evidence Into Practice: Evidence-Based Interventions for Chemotherapy-Induced Peripheral Neuropathy / Clinical Journal of Oncology Nursing
D. J. Storey / 2010 / Capecitabine Combined with Oxaliplatin(CapOx) in Clinical Practice: How Significnat is Peripheral Neuropathy? / Annals of Oncology 21 (8) : 1657 ~ 1661
Frederick H. Hausheera / 2006 / Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy / Semin Oncol 33 : 15 ~ 49
Gamelin E / 2002 / Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventative measures / Semin Oncol 29 (5) : 21 ~ 33
Constance Visovsky / 2007 / Putting Evidence Into Practice: Evidence-Based Interventions for Chemotherapy-Induced Peripheral Neuropathy / Clinical Journal of Oncology Nursing
D. J. Storey / 2010 / Capecitabine Combined with Oxaliplatin(CapOx) in Clinical Practice: How Significnat is Peripheral Neuropathy? / Annals of Oncology 21 (8) : 1657 ~ 1661
Frederick H. Hausheera / 2006 / Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy / Semin Oncol 33 : 15 ~ 49
Gamelin E / 2002 / Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventative measures / Semin Oncol 29 (5) : 21 ~ 33
이 논문의 저자 정보
최근 본 자료
댓글(0)
0